# EDGAR Filing Document

**Accession Number:** 0001910456
**File Stem:** 0001193125-25-311358
**Filing Date:** 2025-12
**Character Count:** 4934
**Document Hash:** fef837113b4a45f78fec9002add9e5c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-311358.hdr.sgml**: 20251208

**ACCESSION NUMBER**: 0001193125-25-311358

**CONFORMED SUBMISSION TYPE**: DFAN14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251208

**DATE AS OF CHANGE**: 20251208

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neuphoria Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001191070
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** DFAN14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41157
- **FILM NUMBER:** 251556750

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SUMMIT DR
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 781-439-5551

**MAIL ADDRESS:**
- **STREET 1:** 100 SUMMIT DR
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BIONOMICS LIMITED/FI
- **DATE OF NAME CHANGE:** 20020920
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lynx1 Capital Management LP
- **CENTRAL INDEX KEY:** 0001910456

**ORGANIZATION NAME:**
- **EIN:** 851134656
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231
- **LEGAL ENTITY IDENTIFIER:** 5493003YH8Q5SHT17216

**FILING VALUES:**
- **FORM TYPE:** DFAN14A

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** D81 CALLE C
- **STREET 2:** SUITE 301 PMB 1202
- **CITY:** DORADO
- **PROVINCE COUNTRY:** PR
- **ZIP:** 00646
- **BUSINESS PHONE:** 703-963-7214

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** D81 CALLE C
- **STREET 2:** SUITE 301 PMB 1202
- **CITY:** DORADO
- **PROVINCE COUNTRY:** PR
- **ZIP:** 00646

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A** 

**(Rule 14a-101)** 

**INFORMATION REQUIRED IN PROXY STATEMENT** 

**SCHEDULE 14A INFORMATION** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

Filed by the Registrant ☐

Filed by a Party other than the Registrant ☒

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Under Rule 14a-12

**NEUPHORIA THERAPEUTICS INC.** 

**(Name of Registrant as Specified in Its Charter)** 

**LYNX1 MASTER FUND LP** 

**LYNX1 CAPITAL MANAGEMENT LP** 

**WESTON NICHOLS** 

**NATHALI PARTYKA ZAMORA** 

**STEPHEN DOBERSTEIN** 

**KIMBERLY SMITH** 

**(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)** 

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Lynx1 Master Fund LP, together with its affiliates (collectively, "**Lynx1**"), has filed a definitive proxy statement and accompanying **BLUE** universal proxy card with the U.S. Securities and Exchange Commission to solicit proxies for the election of Lynx1's slate of highly qualified independent director candidates at the 2025 annual meeting of stockholders of Neuphoria Therapeutics Inc., a Delaware corporation (the "**Company**").

On December 8, 2025, Lynx1 disseminated an audio message to the Company's stockholders. The written transcript of that message is set forth below.

------

<u>Lynx1 Audio Message Transcript</u> 

(0:00): Hi, this is Weston Nichols, Founder of Lynx1 Capital Management.

(0:07): I am calling you because, as a fellow shareholder of Neuphoria Therapeutics, we are concerned about the recent actions taken by the current Board.

(0:18): The Board has demonstrated a failure of judgement, execution and oversight, which ultimately has led to the failure of the AFFIRM-1 trial and extreme dilution of Neuphoria stockholders.

(0:34): We believe fresh, independent perspectives are needed in the boardroom.

(0:40): This is why we have nominated two highly qualified candidates to the Board, who we believe will ensure the Company is set back on a path that delivers on the Company's vision and maximizes shareholder value.

(0:59): Your vote is essential at this critical juncture.

(1:03): The annual meeting is just days away on December 12th.

(1:08): We are urging you to vote your Neuphoria shares in favor of Lynx1's nominees, Stephen Doberstein and Kimberly Smith, on Lynx1's blue card as soon as possible.

(1:23): If you have any questions, please call our proxy firm, Okapi Partners, toll-free at (877) 629-6356.

(1:36): Again, that number is (877) 629-6356.

(1:44): Protect your investment in Neuphoria by voting on the blue proxy card.

(1:50): Thank you in advance for your support.